Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $16
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $17 to $16.
Last updated: 2026-11-19 05:59:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
LeonaBio, Inc. (LONA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.61, with a market capitalization of $30.43M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.21 to $14.21. This page covers its latest market performance, valuation, price trends and company information.
$30.43M | |
$2.77 | |
$3.05 | |
$2.56 | |
$2.76 | |
42.78K | |
195.74K | |
-- | |
$14.21 | |
$2.21 | |
-- | |
2026-06-30 |
LeonaBio, Inc. (LONA) last closed at $2.61 as of 2026-11-19 00:57:00, down 7.97% ($0.22) from the previous close of $2.76.
During the latest regular trading session, LONA traded between $2.56 and $3.05, with a volume of 42.78K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, LeonaBio, Inc. (LONA) moved from $4.47 to $2.61, representing a decline of 41.63% ($1.86).
The stock traded between $2.56 and $4.80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 49.57 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.3%
LONA is currently trading at $2.61, placing it 3.3% of the way from its 52-week low of $2.21 to its 52-week high of $14.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 19 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to LeonaBio, Inc. and LONA stock.
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $17 to $16.
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.69) by 28.99 percent. This is a 47.02 percent increase over losses of $(1.68) per share from the
Eligible investors can buy real shares of LeonaBio, Inc. (LONA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LONA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LONA shares and USD.
LONA Shares to USD
1.00 LONA shares = 2.609 USD
Calculations are estimates based on the latest available price and are for reference only.